---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-081601"
form_type: "8-K"
ticker: "CGEM"
cik: "0001789972"
company_name: "Cullinan Therapeutics, Inc."
filed_at: "2025-06-04T23:59:59+00:00"
generated_at: "2026-05-20T00:07:25.801276+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cullinan licenses BCMAxCD3 bispecific velinotamig from Genrix for $20M upfront, up to $692M milestones

## Summary
- Upfront license fee of $20 million; Genrix eligible for up to $292M in development/regulatory milestones and up to $400M in sales-based milestones.
- Tiered royalties on ex-Greater China net sales ranging from mid-single digit to mid-teens percent.
- Velinotamig has shown potential best-in-class efficacy in ~50 relapsed/refractory multiple myeloma patients; Cullinan to develop in autoimmune diseases.
- Genrix plans Phase 1 autoimmune study in China by end of 2025; Cullinan will conduct global development after that.
- Cullinan reiterates cash runway into 2028 based on current operating plan.

## SEC filing metadata
- accession: 0000950170-25-081601
- form_type: 8-K
- ticker: CGEM
- cik: 0001789972
- company_name: Cullinan Therapeutics, Inc.
- filed_at: 2025-06-04T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789972/000095017025081601/0000950170-25-081601-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789972/000095017025081601/cgem-20250604.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-081601
- JSON: https://secwatch.observer/filing/0000950170-25-081601.json
- Plain text: https://secwatch.observer/filing/0000950170-25-081601.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.